RecruitingNCT01193088

Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2

Genetics of Charcot Marie Tooth Disease (CMT) - Modifiers of CMT1A, New Causes of CMT


Sponsor

University of Iowa

Enrollment

1,050 participants

Start Date

May 1, 2010

Study Type

OBSERVATIONAL

Conditions

Summary

This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.


Eligibility

Inclusion Criteria12

  • All patients must agree to take part in the study and sign a consent form. A teenager (age 13-17 years) considering enrolling must agree to take part in the study and sign an assent form (depending on local ethics committee requirements).
  • Patients must have at least one of the following:
  • Patient has a documented PMP22 duplication. AND/OR
  • Patient has a first or second degree relative (parent, child, sibling, half- sibling, aunt, uncle, grandparent, grandchild, niece, or nephew) with a documented PMP22 duplication AND a clear link between that family member and the affected patient AND a phenotype consistent with CMT1A.
  • i. A clear link is necessary for a second-degree relative. For example, if a grandparent is affected and has a PMP22 duplication, and the parent does not have any signs, symptoms, or electrophysiology consistent with CMT1A, there is no clear link.
  • ii. In cases where clear links are not available, genetic testing is required for the patient or the first degree family member who is not clearly affected.
  • a. Patient has demonstrated neuropathy on nerve conduction studies or clinically diagnosed genetic neuropathy, in the opinion of the investigator or genetic counsellor.
  • Person is a family member of a CMT patient who is enrolled in the CMT Exome Project.
  • AND one of the following:
  • Person does not have a peripheral neuropathy, in the opinion of the investigator or genetic counsellor.
  • OR
  • Person is suspected to have a peripheral neuropathy, but has not been examined at an INC site.

Exclusion Criteria3

  • Patient does not wish to participate or does not sign a consent form.
  • For CMT Exome Project, patient has a genetically confirmed form of CMT (i.e. mutation in MFN2 causing CMT2A, mutation in GARS causing CMT2D, etc.).
  • Patients with known neuropathy from a non-genetic source, such as chemotherapies (i.e. Vincristine, Taxol, Cisplatin), diabetes, alcoholism will be evaluated independently so that genetic contributions to their effects on CMT1A phenotypes can also be analyzed.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(22)

Cedars-Sinai Medical Center

Los Angeles, California, United States

Stanford University

Palo Alto, California, United States

University of Colorado Hospital

Aurora, Colorado, United States

Connecticut Children's Medical Center

Hartford, Connecticut, United States

University of Miami

Miami, Florida, United States

University of Iowa

Iowa City, Iowa, United States

Johns Hopkins University

Baltimore, Maryland, United States

Harvard/Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

University of Minnesota

Maple Grove, Minnesota, United States

University of Rochester

Rochester, New York, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

Houston Methodist Hospital

Houston, Texas, United States

Seattle Children's Hospital

Seattle, Washington, United States

Children's Hospital of Westmead

Sydney, New South Wales, Australia

The Hospital for Sick Children

Toronto, Ontario, Canada

C. Besta Neurological Institute

Milan, Italy

National Hospital of Neurology and Neurosurgery

London, England, United Kingdom

Dubowitz Neuromuscular Centre

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01193088